Trendlines Group Provides Key Updates Ahead of 2026 AGM and SGM: Strategic Transformation, Portfolio Company Exits, and Capital Management

The Trendlines Group Ltd. has released a comprehensive Q&A addressing shareholder questions ahead of its Annual General Meeting (AGM) and Special General Meeting (SGM) scheduled for April 16, 2026. The responses cover crucial topics including the company’s strategic transformation, investment activities, portfolio company valuations, exits, and executive compensation. Investors should review these updates carefully as they contain several points that could potentially impact share value.

1. Strategic Transformation and Portfolio Exits

• Strategic Focus: Since November 2022, Trendlines has concentrated on supporting advanced-stage portfolio companies with the aim of achieving significant exits. The company did not invest in new portfolio companies in FY2023, instead prioritizing the development and potential exit of existing investments.
• Exit Status: No new significant exits have occurred since the ten exits announced on August 3, 2023. This means that monetization of portfolio assets has not advanced in the past year, a point investors should note for expectations around near-term liquidity events.
• Ongoing Investment: Contrary to some speculation, Trendlines confirmed it continues to invest in its existing portfolio companies and has not ceased such support.

2. Investment by LH Related Companies and Implications for Minority Shareholders

• Role of LH Investments: LH related companies have been investing alongside Trendlines in portfolio companies on an “arms-length basis.” These investments are essential for the survival and growth of certain portfolio companies, especially when Trendlines faces capital constraints.
• Impact on Trendlines: Management claims that allowing LH’s participation does not disadvantage Trendlines or its minority shareholders. In fact, these investments inject much-needed capital, preventing company closures and reducing the risk of impairments or write-offs.
• Shareholder Concerns Addressed: No AGM or SGM resolutions are being tabled that specifically benefit LH at Trendlines’ expense. The company highlights that portfolio companies often require bridge funding to survive the so-called “valley of death,” and Trendlines cannot fund all opportunities alone.
• Portfolio Valuation: As of December 31, 2025, Trendlines has 28 graduated incubator companies valued at US\$71.87 million. Depending on the exit multiple applied (historical average: 4.4x or up to 9.7x), the potential exit value could range from US\$316.2 million to US\$697.1 million. However, actual exits are subject to market conditions and successful commercialization.

3. Share Capital Management and Fundraising

• Share Capital Increase: The proposal to increase the company’s registered share capital is not tied to any immediate or specific new share issuance. No new shares will be issued except those already approved, and any future placement at more than a 10% discount to prevailing share price will require shareholder approval.
• Use of Exit Proceeds: Management emphasizes that the preferred strategy is to fund investments using proceeds from portfolio exits. However, the timing of exits is uncertain and must be balanced with cash requirements to support ongoing portfolio company development.
• Timing of Exits: The company did not provide specific guidance on when the next significant exit might occur, noting only that updates will be provided when events materialize.

4. CEO Exit Event Bonus Plan and Portfolio Company Valuations

• Alignment with Shareholders: The proposed CEO Exit Event Bonus Plan is structured to align the CEO’s interests with those of shareholders, as the bonus is only granted upon actual exits (cash receipts), not contracted future earnings.
• No Clawback Provisions: The plan does not include malus or clawback provisions if an exit event is later restructured or fails to meet cash-receipt milestones. The bonus is strictly tied to cash actually received.
• Significant Portfolio Company: Phytolon
  • Regulatory Milestones: The FDA approval for Phytolon does not automatically trigger a valuation write-up. Further commercial developments—such as the signing of Master Supply Agreements with partners—may trigger valuation increases.
  • Transition to Commercialization: If Phytolon transitions from R&D to commercial revenue, this is likely to be reflected in its valuation. However, such a valuation increase is not considered an exit event and therefore does not trigger a CEO bonus.

5. Key Takeaways for Investors

• Potential Triggers for Share Price Movement: The timing and magnitude of exits from Trendlines’ portfolio companies remain the most critical potential catalysts for share price appreciation. Investors should closely monitor announcements relating to exits or commercialization milestones, particularly for high-value assets like Phytolon.
• Capital Constraints and Dilution Risk: Trendlines’ reliance on external investors (such as LH) and the possible need for capital raises could impact dilution risk and the company’s ability to maintain stakes in its portfolio companies.
• Executive Compensation: The structure of the CEO’s bonus plan is closely tied to exit performance, which should motivate management to pursue value-realizing transactions.
• No Immediate Share Dilution: There are currently no plans for significant new share issuances beyond what has been previously approved.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review official company disclosures and consult with their financial advisor before making investment decisions. The information presented here is based on the company’s published Q&A in advance of its 2026 AGM and SGM. Future performance and outcomes may differ from management expectations.

View Trendlines Historical chart here